文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向长链非编码RNA RP11-502I4.3可抑制糖尿病视网膜病变中的血管生成趋势。

Targeting long non-coding RNA RP11-502I4.3 inhibits the trend of angiogenesis in diabetic retinopathy.

作者信息

Zeng Lan, Wu Yuhao, Zhu Lijuan, He Junhao, Yuan Yuan, Wang Xiaocong, Tang Kai, Tan Wei

机构信息

Department of Ophthalmology, The First People's Hospital of Zunyi (also known as The Third Affiliated Hospital of Zunyi Medical University), Zunyi, China.

Zunyi Medical University, Zunyi, China.

出版信息

PLoS One. 2025 May 14;20(5):e0312791. doi: 10.1371/journal.pone.0312791. eCollection 2025.


DOI:10.1371/journal.pone.0312791
PMID:40367061
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12077687/
Abstract

Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA RP11-502I4.3 may be involved in angiogenesis associated with DR. We investigated the role of RP11-502I4.3 in DR by examining its regulation of vascular endothelial growth factor (VEGF). We assessed differences in RP11-502I4.3 expression between the control group and streptozotocin-induced diabetic rats or high glucose (HG)-stimulated human retinal microvascular endothelial cells (HRMECs). VEGF expression was measured with and without lentiviral vectors overexpressing RP11-502I4.3. We analysed the structural alterations related to DR after overexpressing RP11-502I4.3. Our analysis revealed that RP11-502I4.3 expression was lower in the retinas of diabetic rats and HG-stimulated HRMECs compared with normal glucose conditions. Overexpressing of RP11-502I4.3 resulted in decreased VEGF levels. Diabetic rats exhibited retinopathy characterised by thinning of the retinal layer thickness, structural changes in the inner and outer nuclear layers, a reduced count of retinal ganglion cells, and the presence of acellular capillaries. The proliferative activity, migration count, and tube formation ability of HG-treated HRMECs were significantly higher than those of the control group. However, these changes were inhibited by RP11-502I4.3 overexpression. Overexpression RP11-502I4.3 might inhibit retinopathy of diabetic rats and HG-induced angiogenesis by downregulating VEGF expression.

摘要

糖尿病视网膜病变(DR)是导致失明的主要原因。我们推测长链非编码RNA RP11-502I4.3可能参与了与DR相关的血管生成过程。我们通过研究RP11-502I4.3对血管内皮生长因子(VEGF)的调控作用,来探究其在DR中的作用。我们评估了对照组与链脲佐菌素诱导的糖尿病大鼠或高糖(HG)刺激的人视网膜微血管内皮细胞(HRMECs)之间RP11-502I4.3表达的差异。在有或无过表达RP11-502I4.3的慢病毒载体的情况下,测量VEGF的表达。我们分析了过表达RP11-502I4.3后与DR相关的结构改变。我们的分析显示,与正常葡萄糖条件相比,糖尿病大鼠视网膜和HG刺激的HRMECs中RP11-502I4.3的表达较低。过表达RP11-502I4.3导致VEGF水平降低。糖尿病大鼠表现出视网膜病变,其特征为视网膜层厚度变薄、内核层和外核层结构改变、视网膜神经节细胞数量减少以及无细胞毛细血管的存在。HG处理的HRMECs的增殖活性、迁移数量和管形成能力显著高于对照组。然而,这些变化被RP11-502I4.3过表达所抑制。过表达RP11-502I4.3可能通过下调VEGF表达来抑制糖尿病大鼠的视网膜病变和HG诱导的血管生成。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/c520c1e2d847/pone.0312791.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/ce5a344ddd51/pone.0312791.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/3b359c4222ae/pone.0312791.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/3e5ce3c8ea82/pone.0312791.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/1e97d32415b2/pone.0312791.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/46fd14261107/pone.0312791.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/aca7b166b934/pone.0312791.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/c520c1e2d847/pone.0312791.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/ce5a344ddd51/pone.0312791.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/3b359c4222ae/pone.0312791.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/3e5ce3c8ea82/pone.0312791.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/1e97d32415b2/pone.0312791.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/46fd14261107/pone.0312791.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/aca7b166b934/pone.0312791.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d74/12077687/c520c1e2d847/pone.0312791.g007.jpg

相似文献

[1]
Targeting long non-coding RNA RP11-502I4.3 inhibits the trend of angiogenesis in diabetic retinopathy.

PLoS One. 2025-5-14

[2]
MicroRNA-199a-3p inhibits angiogenesis by targeting the VEGF/PI3K/AKT signalling pathway in an in vitro model of diabetic retinopathy.

Exp Mol Pathol. 2020-7-2

[3]
Preliminary research on LncRNA ATP2B2-IT2 in neovascularization of diabetic retinopathy.

BMC Ophthalmol. 2024-6-21

[4]
MiR-203a-3p inhibits retinal angiogenesis and alleviates proliferative diabetic retinopathy in oxygen-induced retinopathy (OIR) rat model via targeting VEGFA and HIF-1α.

Clin Exp Pharmacol Physiol. 2020-1

[5]
Circular RNA COL1A2 promotes angiogenesis via regulating miR-29b/VEGF axis in diabetic retinopathy.

Life Sci. 2020-6-1

[6]
LncRNA-MALAT1 promotes neovascularization in diabetic retinopathy through regulating miR-125b/VE-cadherin axis.

Biosci Rep. 2019-5-15

[7]
Repression of microRNA-21 inhibits retinal vascular endothelial cell growth and angiogenesis via PTEN dependent-PI3K/Akt/VEGF signaling pathway in diabetic retinopathy.

Exp Eye Res. 2019-11-21

[8]
Long noncoding RNA MALAT1 participates in the pathological angiogenesis of diabetic retinopathy in an oxygen-induced retinopathy mouse model by sponging miR-203a-3p.

Can J Physiol Pharmacol. 2019-11-5

[9]
A novel regulatory network of linc00174/miR-150-5p/VEGFA modulates pathological angiogenesis in diabetic retinopathy.

Can J Physiol Pharmacol. 2021-11

[10]
YAP1 is required for the angiogenesis in retinal microvascular endothelial cells via the inhibition of MALAT1-mediated miR-200b-3p in high glucose-induced diabetic retinopathy.

J Cell Physiol. 2019-7-16

本文引用的文献

[1]
Cell and molecular targeted therapies for diabetic retinopathy.

Front Endocrinol (Lausanne). 2024

[2]
The role of long noncoding RNAs in ocular angiogenesis and vascular oculopathy.

Cell Biosci. 2024-3-23

[3]
Recent advances in the treatment and delivery system of diabetic retinopathy.

Front Endocrinol (Lausanne). 2024

[4]
Research progress on the pathogenesis of diabetic retinopathy.

BMC Ophthalmol. 2023-9-11

[5]
Long Non-Coding RNAs and Proliferative Retinal Diseases.

Pharmaceutics. 2023-5-10

[6]
Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases.

Adv Drug Deliv Rev. 2023-7

[7]
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.

Cochrane Database Syst Rev. 2023-3-20

[8]
Aberrant lncRNA expression in patients with proliferative diabetic retinopathy: preliminary results from a single-center observational study.

BMC Ophthalmol. 2023-3-10

[9]
Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.

Cochrane Database Syst Rev. 2023-2-22

[10]
Noncoding RNAs Are Promising Therapeutic Targets for Diabetic Retinopathy: An Updated Review (2017-2022).

Biomolecules. 2022-11-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索